Quantcast

Reportlinker Adds Bulk Paclitaxel – A Global Update of Market Trends & Opportunities

December 8, 2009

NEW YORK, Dec. 8 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Bulk Paclitaxel – A Global Update of Market Trends & Opportunities

http://www.reportlinker.com/p0164226/Bulk-Paclitaxel—A-Global-Update-of-Market-Trends–Opportunities.html

World bulk paclitaxel market stands enthused by the effervescent levels of research and development. With market participants injecting resources into developing unique paclitaxel formulations, emergence of new disease indications is expected to result in expanded market opportunities in the medium to long run. For instance, development of paclitaxel-coated coronary stents will help further improve the use and sales of paclitaxel. With patent expiries leading to the influx of generic forms of paclitaxel, competition is expected to intensify and result in price reductions.

These and other market data and trends are presented in “Bulk Paclitaxel: A Global Update of Market Trends & Opportunities” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

BULK PACLITAXEL BMR-1026

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. INDUSTRY OVERVIEW 3

Paclitaxel – Leading from the Front 3

US Market – Magnificently Outdistancing Others 4

Cancer Blockbusters – Facing the Brunt 4

A Sunrise Opportunity 4

BMS’ Reign Comes to an End 4

Exploring New Avenues 5

Falling Prices – Boon for The Customers, Bane for The Companies 6

All the Strangle for Peanuts? 6

Factors Affecting the Market 6

Paclitaxel Versus Abraxane 7

3. OUTLOOK 7

Competitive Scenario 8

Cancer Generics – A Time for Optimism 8

The US Piazza 8

4. PRODUCT FACTS 9

5. RESEARCH AND DEVELOPMENT 10

Angiotech Unfurls New Dimensions for Paclitaxel 10

Clinical Research Favors Paclitaxel for Breast Cancer Treatment 11

American BioScience’ Nab Technology Unveils Higher Tissue

Penetration Potential 11

Naturol Develops Unique Extraction Technology for Producing

Paclitaxel from Canadian Yew 11

Ivax Corp.’s Xorane Revolutionizes the Delivery of Paclitaxel 12

6. CORPORATE DEVELOPMENTS 13

Sonus to Merge with OncoGenex 13

Acusphere Signs Licensing Deal with Cephalon 13

Sonus Terminates TOCOSOL Paclitaxel Development Program 13

Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel 13

Pliva Lachema Receives ANDA for Paclitaxel Injection 14

Cell Therapeutics Receives EMEA Acceptance 14

Abraxis Wins Approval for ABRAXANE in Korea 14

Boston Scientific Obtains Approval for TAXUS® Liberte® from

Health Canada 14

Cell Therapeutics Renames Xyotax as Opaxio 14

Dabur Launches Cancer Drug 14

Hospira Takes Over Mayne Pharma 14

Protherics to Acquire MacroMed 15

Abraxis Acquires Arizona Production Facility 15

Indena Inks Worldwide License Agreement with Spectrum Pharma 15

Bioxel Bags Major Paclitaxel Order 16

Bioxel Enters into Supply Agreement 16

Bioxel Bags Paclitaxel Supply Contract 16

Indena Establishes New Plant to Produce Synthetic Paclitaxel 16

Abraxis Selects Korean Green Cross to Market ABRAXANE® 17

Abraxis Grants License to Biocon for Marketing ABRAXANE® 17

Bioxel Registers Docetaxel with US FDA 17

Bayer Quashes TOCOSOL Paclitaxel License with Sonus 17

Abraxis’ ABRAXANE Convinces European CHMP 18

Abraxis Receives Approval for ABRAXANE in Australia 18

Eurocor Receives CE Mark 18

SuperGen Divests Certain Drugs to Intas 18

Abraxis Plans Separation of Oncology Business 18

Dabur Introduces Nanoxel 19

7. MAJOR PLAYERS 19

Abraxis BioScience, Inc. (USA) 19

Bristol-Myers Squibb Co. (USA) 19

Hospira, Inc. (USA) 20

Indena S.p.A. (Italy) 20

OncoGenex Pharmaceuticals, Inc. (USA) 20

Teva Pharmaceuticals USA, Inc. (USA) 20

8. MARKET ANALYTICS 21

9. THE UNITED STATES 22

Rising Demand for Paclitaxel 23

Alarming Growth of Breast Cancer 23

Clinical Research Favors Paclitaxel for Breast Cancer Treatment 23

Paclitaxel – An Important Element 23

Corporate Talk 23

Drug-Eluting Stents – Marching Ahead 24

10. REST OF WORLD 25

Europe 25

European Market Overview 25

European Market Battling Cost- Containment Woes 25

Efforts to Improve the Scenario and their Effect on

Paclitaxel Market 26

China 26

Chinese Government Strategizing to Save Paclitaxel Reserves 26

EXHIBITS

Table 1: Global Bulk Paclitaxel Market by Region for the Period

2007-2015 (Sales in Kilograms)

Table 2: Percentage Breakdown (Volume Sales) of Global Bulk

Paclitaxel Market by Region for the Years 2008 & 2012

Table 3: Global Bulk Paclitaxel Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 4: Percentage Breakdown (Dollar Sales) of Global Bulk

Paclitaxel Market by Region for the Years 2008 & 2012

Table 5: Bulk Paclitaxel Market in the US: 2007-2015 (Sales in

Kilograms)

Table 6: Bulk Paclitaxel Market in the US: 2007-2015 (Sales

in US$ Million)

Table 7: Bulk Paclitaxel Market in Rest of World: 2007-2015

(Sales in Kilograms)

Table 8: Bulk Paclitaxel Market in Rest of World: 2007-2015

(Sales in US$ Million)

COMPANIES PROFILED

To order this report:

Pharmaceutical Industry: Bulk Paclitaxel – A Global Update of Market Trends & Opportunities

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus